B细胞样T细胞的发现

Objective: We found that there is a special cell in the peripheral blood of cancer patients, which express both the surface marker CD19 of B lymphocytes and the surface marker CD3 of T lymphocytes, which we call B cell-like T cells (CD19+CD3+, hereinafter referred to as B-T cells), and compared with healthy volunteers, and analyzed its expression and possible value in cancer patients. Methods:A total of 267 patients with malignant tumor were enrolled in the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine from May 2013 to February 2016, and 62 healthy volunteers were recruited as the control group.The levels of CD19+CD3+ cells in peripheral blood were measured by flow cytometry, and the differences between the two groups were compared. Results: The percentage of B-T cells in peripheral blood of healthy volunteers was 0.12%. The percentage of B-T cells in peripheral blood of cancer patients was 0.45%,and the percentage of B-T cells in cancer patients was significantly higher than that in healthy volunteers, the difference was statistically significant (P <0.01).And P25 in the percentage of B-T cells in cancer patients was significantly higher than P75 in the percentage of B-T cells in healthy volunteers,with significant differences.There was no significant correlation between the percentage of B-T cells and lymphocyte subsets in peripheral blood of cancer patients (P> 0.05).The percentages of B-T cells in different tumor species were different. The percentages of B-T cells were high in esophageal cancer, non-Hodgkin's lymphoma and liver cancer, and were low in ovarian cancer and renal carcinoma,and there was significant difference between the highest esophageal carcinoma and the lowest renal carcinoma (P <0.05).The distribution of B-T cells in gastric cancer, ovarian cancer and pancreatic cancer was more concentrated, but the distribution of B-T cells in liver cancer, esophageal cancer and breast cancer was more dispersed.For cancer patients,there was no significant difference in the percentage of B-T cells in different age groups, different sexes, different clinical stages, with or without metastasis, lymph node metastasis, and splenomegaly (P> 0.05). Conclusion:B-T cells were present in peripheral blood of healthy volunteers and cancer patients, and the percentage of B-T cells in cancer patients was significantly higher than that of healthy volunteers, which could be a marker of tumor immune injury.